RNA Therapy Deals Heat Up: AbbVie, Eli Lilly, and Jingyin Pharma Announce Major Collaborations

5Month20Date, Sirius Therapeutics andCRISPR TherapeuticsAnnounce that the two parties have reached a strategic partnership and will work together to promotesiRNAJoint Development and Commercialization of the Therapy. The press release stated that this collaboration combines the complementary capabilities of both parties in research and development and industrialization, jointly developing and commercializing the next generation of long-actingFactor XI（FXI) Targeted small interferingRNA（siRNA`) Therapy`SRSD107, used for the treatment of thrombosis and thromboembolic diseases.

According to the terms of the agreement, Sirius Therapeutics will receiveCRISPR TherapeuticsPaid9500Million US dollars in cash and cash equivalents as the upfront payment, with eligibility for additional8Hundreds of millions of dollars in upfront and milestone payments. The two parties will50-50The cost and profit sharing mechanism for joint developmentSRSD107. In addition, the agreement also grantsCRISPR TherapeuticsIn the future, exclusively introduce up to two additionalsiRNAThe right to priority authorization of the project.

Recently,AbbVie (AbbVie) andADARx PharmaceuticalsAnnounced the achievement of a collaboration and license option agreement aimed at jointly developing treatments for multiple disease areas.siRNATherapies, these fields include neuroscience, immunology, and oncology. 

Image Source: AbbVie Corporate Website

This strategic cooperation will give full play toADARxInRNAProfessional competence in discovery and its proprietarysiRNATechnology, which is expected to achieve lasting and precisemRNASilence. AbbVie, on the other hand, will provide professional support in antibody engineering, antibody-drug conjugates, and tissue delivery strategies to assist.ADARxDrug discovery efforts. According to the terms of the agreement,ADARxWill Obtain3.35Hundreds of millions of dollars in upfront payments and is eligible to receive billions of dollars, including milestone payments.。

5Month15Day, Korean biopharmaceutical companyRznomicsAnnounced collaboration with Eli Lilly (Eli Lilly) to reach a global R&D collaboration and licensing agreement to jointly develop based onRNAGene-Editing Technology for Hereditary Hearing Loss Therapy. According to the agreement, if Lilly exercises all collaboration options, the total transaction value will exceed13Hundreds of millions of dollars, plus sales royalties.

Image Source:RznomicsOfficial Website

According to public information, the focus of this collaboration is on the discovery and development for sensorineural hearing loss.TheRNAEditing Therapy.RznomicsEarly research will be conducted according to a jointly approved study plan, while Eli Lilly and Company will be responsible for further development and commercialization.

Editor: Chen Lina

Layout Editor: Yu Yuanze

Reviewed by: Ma Fei, Zhang Song

Results of 66 Chemical Drug Joint Purchases Released! Maximum Price Reduction Exceeds 98%, Can Volume-Based Linkage Further Explore the Price Floor?

Tao Jianhong: Lighting the Way for Innovation Overseas – Analyzing the Southern Force Behind China’s Innovative Drug Exports

Lin Jianning: According to the calculations by the Southern Institute, this year's pharmaceutical revenue increased by 1.6%, and terminal growth was 2.3%.

www.yyjjb.com.cn

Insight into Industry Trends

Long press to followPharmaceutical Economy Report

《China Prescription Drug》

Academic Official Account

Focus on Pharmaceutical Academics and Evidence-Based Research

Long press to followChina Prescription Drug    

Pharmaceutical Economy Herald

Terminal Official Account

Record Major Events in the Pharmaceutical Industry

Long press to follow21st Century Pharmacy